DETECTION OF GENETIC ABNORMALITIES

• US 20120190020A1
• Filed: 01/23/2012
• Published: 07/26/2012
• Est. Priority Date: 01/25/2011
• Status: Abandoned Application

• Current Assignee: Roche Molecular Systems Inc (Roche Holding AG)
• Original Assignee: Ariosa Diagnostics Incorporated (Roche Holding AG)
• Inventors: Oliphant, Arnold, Sparks, Andrew, Song, Ken, Stuelpnagel, John
• Application Number:
  US13/356,133
• Publication Number:
  US 20120190020A1
• Time in Patent Office: Days
• US Class Current: 435/6.11
• CPC Class Codes: C12Q 1/6827 for detection of mutation or polymorphism
• CPC Class Codes: C12Q 1/6883 for diseases caused by alterations of genetic material
• CPC Class Codes: C12Q 2600/156 Polymorphic or mutational markers

Abstract

The present invention provides assay systems and related methods for determining genetic abnormalities in mixed samples comprising cell free DNA from both normal and putative genetically atypical cells. Exemplary mixed samples for analysis using the assay systems of the invention include samples comprising both maternal and fetal cell free DNA and samples that contain DNA from normal cells and circulating cancerous cells.

Claims

1. An assay system for detection of the presence or absence of a fetal chromosomal abnormality comprising the steps of:

providing a mixed sample comprising cell free DNA;

isolating two or more selected non-polymorphic nucleic acid regions from a first genomic region of interest in the mixed sample;

isolating two or more selected non-polymorphic nucleic acid regions from a second genomic region of interest in the mixed sample;

amplifying the selected nucleic acid regions from the first and second genomic regions using one or more rounds of amplification;

detecting the amplified nucleic acid regions;

quantifying a relative frequency of the selected nucleic acid regions from the first and second genomic regions of interest;

comparing the relative frequency of the selected nucleic acid regions from the first and second genomic regions of interest; and

identifying the presence or absence of a fetal chromosomal abnormality based on the compared relative frequency.

2. The assay system of claim 1, wherein the chromosomal abnormality is an insertion or duplication.

3. The assay system of claim 1, wherein the chromosomal abnormality is an aneuploidy.

4. The assay system of claim 1, where the nucleic acid regions are isolated using a selective amplification.

5. The assay system of claim 1, where the nucleic acid regions are isolated using hybridization.

6. The assay system of claim 1, where the nucleic acid regions undergo a universal amplification.

7. The assay system of claim 1, wherein the relative frequencies of the selected nucleic acid regions are individually quantified, and the relative frequencies of the individual nucleic acid regions are compared to determine the presence or absence of an aneuploidy.

8. The assay system of claim 1, wherein the quantified relative frequencies of the selected nucleic acid regions are normalized following detection and prior to quantification.

9. The assay system of claim 1, wherein the selected nucleic acid regions are associated with one or more identifying indices.

10. The assay system of claim 9, wherein the frequency of the selected nucleic acid regions are determined through identification of the associated one or more indices.

11. The assay system of claim 1, where the nucleic acid regions are assayed in a single vessel.

12. The assay system of claim 1, where the nucleic acid regions are each counted an average of at least 250 times.

13. An assay system for detection of the presence or absence of a fetal aneuploidy comprising the steps of:

providing a mixed sample comprising cell free DNA;

isolating two or more selected non-polymorphic nucleic acid regions from a first chromosome of interest in the mixed sample;

isolating two or more selected non-polymorphic nucleic acid regions from a second chromosome of interest in the mixed sample;

amplifying the selected nucleic acid regions from the first and second chromosomes using one or more rounds of amplification;

detecting the amplified nucleic acid regions;

quantifying a relative frequency of the selected nucleic acid regions from the first and second chromosomes of interest;

comparing the relative frequency of the selected nucleic acid regions from the first and second chromosomes of interest; and

identifying the presence or absence of an aneuploidy based on the compared relative frequencies of the first and second chromosome of interest.

14. The assay system of claim 13, where the nucleic acid regions are isolated using a selective amplification.

15. The assay system of claim 13, where the nucleic acid regions are isolated using hybridization.

16. The assay system of claim 13, where the nucleic acid regions undergo a universal amplification.

17. The assay system of claim 13, wherein the relative frequencies of the selected nucleic acid regions are individually quantified, and the relative frequencies of the individual nucleic acid regions are compared to determine the presence or absence of an aneuploidy.

18. The assay system of claim 13, wherein the quantified relative frequencies of the nucleic acid regions are used to determine a chromosome frequency of the first and second chromosomes of interest, and wherein the presence or absence of an aneuploidy is based on the compared chromosome frequencies of the first and second chromosomes of interest.

19. The assay system of claim 13, wherein the quantified relative frequencies of the selected nucleic acid regions are normalized following detection and prior to quantification.

20. The assay system of claim 13, wherein at least forty eight nucleic acid regions are selected for each chromosome of interest.

21. The assay system of claim 20, wherein at least ninety six nucleic acid regions are selected for each chromosome of interest.

22. The assay system of claim 13, wherein the selected nucleic acid regions are associated with one or more identifying indices.

23. The assay system of claim 22, wherein the frequency of the selected nucleic acid regions are determined through identification of the associated one or more indices.

24. The assay system of claim 13, where the nucleic acid regions are assayed in a single vessel.

25. The assay system of claim 13, where the nucleic acid regions are each counted an average of at least 250 times.

26. An assay system for detection of the presence or absence of a fetal aneuploidy comprising the steps of:

providing a maternal sample comprising maternal and fetal cell free DNA;

selectively amplifying two or more nucleic acid regions from a first chromosome of interest in the maternal sample;

selectively amplifying two or more nucleic acid regions from a second chromosome of interest in the maternal sample;

detecting the amplified nucleic acid regions;

quantifying a relative frequency of the selected nucleic acid regions from the first and second chromosomes of interest;

comparing the relative frequency of the selected nucleic acid regions from the first and second chromosomes of interest; and

identifying the presence or absence of a fetal aneuploidy based on the compared relative frequencies of the selected nucleic acid regions.

27. The assay system of claim 26, wherein the maternal sample is maternal blood, maternal plasma or maternal serum.

28. The assay system of claim 27, wherein the maternal sample is maternal plasma.

29. The assay system of claim 26, wherein the relative frequencies of the selected nucleic acid regions are individually calculated, and the relative frequencies of the individual nucleic acid regions are compared to determine the presence or absence of a fetal aneuploidy.

30. The assay system of claim 26, wherein the relative frequencies of the nucleic acid regions are used to determine a chromosome frequency of the first and second chromosomes of interest, and wherein the presence or absence of a fetal aneuploidy is based on the compared chromosomal frequencies of the first and second chromosomes of interest.

31. The assay system of claim 26, wherein the quantified relative frequencies of the selected nucleic acid regions are normalized following detection and prior to quantification.

32. The assay system of claim 26, wherein at least forty-eight nucleic acid regions are selected for each chromosome of interest.

33. The assay system of claim 26, wherein at least ninety-six nucleic acid regions are selected for each chromosome of interest.

34. The assay system of claim 26, wherein the selected nucleic acid regions are associated with one or more identifying indices.

35. The assay system of claim 34, wherein the frequencies of the selected nucleic acid regions are quantified based on identification of the one or more associated indices.

36. The assay system of claim 26, wherein the nucleic acid regions are assayed in a single vessel.

37. The assay system of claim 26, wherein the selective amplification utilizes universal primers.

38. The assay system of claim 26, wherein the nucleic acid regions are each counted an average of at least 250 times.

39. An assay system for detection of the presence or absence of a fetal aneuploidy comprising the steps of:

providing a maternal sample comprising maternal and fetal cell free DNA;

selectively amplifying two or more nucleic acid regions from a chromosome of interest in the maternal sample;

selectively amplifying two or more nucleic acid regions from a reference chromosome in the maternal sample;

determining a relative frequency of the selected nucleic acid regions from the chromosomes of interest and the reference chromosome;

comparing the relative frequency of the selected nucleic acid regions from the chromosomes of interest and the reference chromosome; and

identifying the presence or absence of a fetal aneuploidy based on the compared relative frequencies of the selected nucleic acid regions.

40. The assay system of claim 39, wherein the maternal sample is maternal blood, maternal plasma or maternal serum.

41. The assay system of claim 39, wherein the maternal sample is maternal plasma.

42. The assay system of claim 39, wherein the relative frequencies of the selected nucleic acid regions are individually calculated, and the relative frequencies of the individual nucleic acid regions of the chromosome of interest and the reference chromosome are compared to determine the presence or absence of a fetal aneuploidy.

43. The assay system of claim 39, wherein the relative frequencies of the nucleic acid regions are used to determine a chromosome frequency of the chromosome of interest and the reference chromosome, and wherein the presence or absence of a fetal aneuploidy is based on the compared chromosome frequencies of the chromosome of interest and the reference chromosome.

44. The assay system of claim 39, wherein the quantified relative frequencies of the selected nucleic acid regions are normalized following detection and prior to quantification.

45. The assay system of claim 39, wherein at least twenty four nucleic acid regions are selected for each chromosome of interest.

46. The assay system of claim 45, wherein at least forty eight nucleic acid regions are selected for each chromosome of interest.

47. The assay system of claim 39, wherein the selected nucleic acid regions are associated with one or more identifying indices.

48. The assay system of claim 47, wherein the frequencies of the selected nucleic acid regions are quantified based on identification of the one or more associated indices.